Cogent Biosciences, Inc.
COGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1,157 | $0 | $0 |
| Gross Profit | $0 | -$1,157 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $68,989 | $61,046 | $63,029 | $62,045 |
| G&A Expenses | $14,366 | $13,379 | $11,904 | $11,689 |
| SG&A Expenses | $14,366 | $13,379 | $11,904 | $11,689 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $83,355 | $74,425 | $74,933 | $73,734 |
| Operating Income | -$83,355 | -$75,582 | -$74,933 | -$73,734 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,425 | $2,053 | $2,947 | $5,807 |
| Pre-Tax Income | -$80,930 | -$73,529 | -$71,986 | -$67,927 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$80,930 | -$73,529 | -$71,986 | -$67,927 |
| % Margin | – | – | – | – |
| EPS | -0.71 | -0.64 | -0.52 | -0.61 |
| % Growth | -10.9% | -23.1% | 14.8% | – |
| EPS Diluted | -0.71 | -0.64 | -0.52 | -0.61 |
| Weighted Avg Shares Out | 114,466 | 114,466 | 113,308 | 110,462 |
| Weighted Avg Shares Out Dil | 114,466 | 114,466 | 113,308 | 110,462 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,887 | $2,373 | $2,952 | $3,859 |
| Interest Expense | $1,459 | $314 | $0 | $0 |
| Depreciation & Amortization | $641 | $1,157 | $1,138 | $1,108 |
| EBITDA | -$78,830 | -$72,058 | -$73,795 | -$72,626 |
| % Margin | – | – | – | – |